https://www.nejm.org/doi/full/10.1056/NEJMoa2211437
Conclusions: Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified.
Lynch Syndrome Ireland 